Cargando…
Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer
PURPOSE: Prostate cancer (PCa) is one of the most common cancers and one of the leading causes of death worldwide. Thus, one major issue in PCa research is to accurately distinguish between indolent and clinically significant (csPCa) to reduce overdiagnosis and overtreatment. In this study, we aim t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427869/ https://www.ncbi.nlm.nih.gov/pubmed/35841414 http://dx.doi.org/10.1007/s00345-022-04077-1 |
_version_ | 1784778992216178688 |
---|---|
author | Frantzi, Maria Heidegger, Isabel Roesch, Marie C. Gomez-Gomez, Enrique Steiner, Eberhard Vlahou, Antonia Mullen, William Guler, Ipek Merseburger, Axel S. Mischak, Harald Culig, Zoran |
author_facet | Frantzi, Maria Heidegger, Isabel Roesch, Marie C. Gomez-Gomez, Enrique Steiner, Eberhard Vlahou, Antonia Mullen, William Guler, Ipek Merseburger, Axel S. Mischak, Harald Culig, Zoran |
author_sort | Frantzi, Maria |
collection | PubMed |
description | PURPOSE: Prostate cancer (PCa) is one of the most common cancers and one of the leading causes of death worldwide. Thus, one major issue in PCa research is to accurately distinguish between indolent and clinically significant (csPCa) to reduce overdiagnosis and overtreatment. In this study, we aim to validate the usefulness of diagnostic nomograms (DN) to detect csPCa, based on previously published urinary biomarkers. METHODS: Capillary electrophoresis/mass spectrometry was employed to validate a previously published biomarker model based on 19 urinary peptides specific for csPCa. Added value of the 19-biomarker (BM) model was assessed in diagnostic nomograms including prostate-specific antigen (PSA), PSA density and the risk calculator from the European Randomized Study of Screening. For this purpose, urine samples from 147 PCa patients were collected prior to prostate biopsy and before performing digital rectal examination (DRE). The 19-BM score was estimated via a support vector machine-based software based on the pre-defined cutoff criterion of − 0.07. DNs were subsequently developed to assess added value of integrative diagnostics. RESULTS: Independent validation of the 19-BM resulted in an 87% sensitivity and 65% specificity, with an AUC of 0.81, outperforming PSA (AUC (PSA): 0.64), PSA density (AUC (PSAD): 0.64) and ERSPC-3/4 risk calculator (0.67). Integration of 19-BM with the rest clinical variables into distinct DN, resulted in improved (AUC range: 0.82–0.88) but not significantly better performances over 19-BM alone. CONCLUSION: 19-BM alone or upon integration with clinical variables into DN, might be useful for detecting csPCa by decreasing the number of biopsies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-022-04077-1. |
format | Online Article Text |
id | pubmed-9427869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94278692022-09-01 Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer Frantzi, Maria Heidegger, Isabel Roesch, Marie C. Gomez-Gomez, Enrique Steiner, Eberhard Vlahou, Antonia Mullen, William Guler, Ipek Merseburger, Axel S. Mischak, Harald Culig, Zoran World J Urol Original Article PURPOSE: Prostate cancer (PCa) is one of the most common cancers and one of the leading causes of death worldwide. Thus, one major issue in PCa research is to accurately distinguish between indolent and clinically significant (csPCa) to reduce overdiagnosis and overtreatment. In this study, we aim to validate the usefulness of diagnostic nomograms (DN) to detect csPCa, based on previously published urinary biomarkers. METHODS: Capillary electrophoresis/mass spectrometry was employed to validate a previously published biomarker model based on 19 urinary peptides specific for csPCa. Added value of the 19-biomarker (BM) model was assessed in diagnostic nomograms including prostate-specific antigen (PSA), PSA density and the risk calculator from the European Randomized Study of Screening. For this purpose, urine samples from 147 PCa patients were collected prior to prostate biopsy and before performing digital rectal examination (DRE). The 19-BM score was estimated via a support vector machine-based software based on the pre-defined cutoff criterion of − 0.07. DNs were subsequently developed to assess added value of integrative diagnostics. RESULTS: Independent validation of the 19-BM resulted in an 87% sensitivity and 65% specificity, with an AUC of 0.81, outperforming PSA (AUC (PSA): 0.64), PSA density (AUC (PSAD): 0.64) and ERSPC-3/4 risk calculator (0.67). Integration of 19-BM with the rest clinical variables into distinct DN, resulted in improved (AUC range: 0.82–0.88) but not significantly better performances over 19-BM alone. CONCLUSION: 19-BM alone or upon integration with clinical variables into DN, might be useful for detecting csPCa by decreasing the number of biopsies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-022-04077-1. Springer Berlin Heidelberg 2022-07-16 2022 /pmc/articles/PMC9427869/ /pubmed/35841414 http://dx.doi.org/10.1007/s00345-022-04077-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Frantzi, Maria Heidegger, Isabel Roesch, Marie C. Gomez-Gomez, Enrique Steiner, Eberhard Vlahou, Antonia Mullen, William Guler, Ipek Merseburger, Axel S. Mischak, Harald Culig, Zoran Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer |
title | Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer |
title_full | Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer |
title_fullStr | Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer |
title_full_unstemmed | Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer |
title_short | Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer |
title_sort | validation of diagnostic nomograms based on ce–ms urinary biomarkers to detect clinically significant prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427869/ https://www.ncbi.nlm.nih.gov/pubmed/35841414 http://dx.doi.org/10.1007/s00345-022-04077-1 |
work_keys_str_mv | AT frantzimaria validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT heideggerisabel validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT roeschmariec validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT gomezgomezenrique validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT steinereberhard validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT vlahouantonia validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT mullenwilliam validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT guleripek validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT merseburgeraxels validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT mischakharald validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer AT culigzoran validationofdiagnosticnomogramsbasedoncemsurinarybiomarkerstodetectclinicallysignificantprostatecancer |